Do analysts recommend JSPR or PBM?

Jasper Therapeutics currently has a consensus target price of $13.14, suggesting a potential upside of 2,578.94%. Given Jasper Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Jasper Therapeutics is more favorable than Psyence Biomedical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jasper Therapeutics 1 Sell rating(s) 6 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.33 Psyence Biomedical 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, JSPR or PBM?

Jasper Therapeutics is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Jasper Therapeutics N/A N/A -$75.80M -$3.23 N/A Psyence Biomedical N/A N/A $1.01M $25.34 0.11

Is JSPR or PBM more profitable?

Psyence Biomedical's return on equity of 0.00% beat Jasper Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Jasper Therapeutics N/A -613.51% -162.52% Psyence Biomedical N/A N/A N/A

Do analysts prefer BFRI or PBM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biofrontera 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Psyence Biomedical 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend KTTA or PBM?

Pasithea Therapeutics currently has a consensus target price of $3.00, suggesting a potential upside of 439.67%. Given Pasithea Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Pasithea Therapeutics is more favorable than Psyence Biomedical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pasithea Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Psyence Biomedical 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, KTTA or PBM?

Pasithea Therapeutics is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pasithea Therapeutics N/A N/A -$20.43M -$2.08 N/A Psyence Biomedical N/A N/A $1.01M $25.34 0.11

Is KTTA or PBM more profitable?

Psyence Biomedical's return on equity of 0.00% beat Pasithea Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Pasithea Therapeutics N/A -57.44% -53.61% Psyence Biomedical N/A N/A N/A

Do analysts prefer AKTX or PBM?

Akari Therapeutics currently has a consensus price target of $89.00, indicating a potential upside of 727.14%. Given Akari Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Akari Therapeutics is more favorable than Psyence Biomedical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Akari Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Psyence Biomedical 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, AKTX or PBM?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Akari Therapeutics N/A N/A -$17.30M N/A N/A Psyence Biomedical N/A N/A $1.01M $25.34 0.11

Is AKTX or PBM more profitable?

Psyence Biomedical's return on equity of 0.00% beat Akari Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Akari Therapeutics N/A -123.29% -63.01% Psyence Biomedical N/A N/A N/A

Which has stronger earnings & valuation, PHIO or PBM?

Phio Pharmaceuticals is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Phio Pharmaceuticals N/A N/A -$8.70M -$1.38 N/A Psyence Biomedical N/A N/A $1.01M $25.34 0.11

Is PHIO or PBM more profitable?

Psyence Biomedical's return on equity of 0.00% beat Phio Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Phio Pharmaceuticals N/A -77.34% -70.87% Psyence Biomedical N/A N/A N/A

Psyence Biomedical (PBM) Competitors

$2.75 -0.16 (-5.50%)

Closing price 06/24/2026 04:00 PM Eastern

Extended Trading

$2.89 +0.14 (+5.24%)

As of 06/24/2026 07:48 PM Eastern

Compare

PBM vs. JSPR, BFRI, KTTA, AKTX, and PHIO

Should you buy Psyence Biomedical stock or one of its competitors? MarketBeat compares Psyence Biomedical with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Psyence Biomedical include Jasper Therapeutics (JSPR), Biofrontera (BFRI), Pasithea Therapeutics (KTTA), Akari Therapeutics (AKTX), and Phio Pharmaceuticals (PHIO). These companies are all part of the "pharmaceutical products" industry.

How does Psyence Biomedical compare to Jasper Therapeutics?

Jasper Therapeutics (NASDAQ:JSPR) and Psyence Biomedical (NASDAQ:PBM) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, media sentiment, risk, profitability, dividends and analyst recommendations.

Psyence Biomedical's return on equity of 0.00% beat Jasper Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jasper Therapeutics	N/A	-613.51%	-162.52%
Psyence Biomedical	N/A	N/A	N/A

Jasper Therapeutics has a beta of 3, indicating that its share price is 200% more volatile than the broader market. Comparatively, Psyence Biomedical has a beta of 1.64, indicating that its share price is 64% more volatile than the broader market.

Jasper Therapeutics is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jasper Therapeutics	N/A	N/A	-$75.80M	-$3.23	N/A
Psyence Biomedical	N/A	N/A	$1.01M	$25.34	0.11

79.9% of Jasper Therapeutics shares are owned by institutional investors. Comparatively, 77.4% of Psyence Biomedical shares are owned by institutional investors. 2.3% of Jasper Therapeutics shares are owned by insiders. Comparatively, 3.6% of Psyence Biomedical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Jasper Therapeutics currently has a consensus target price of $13.14, suggesting a potential upside of 2,578.94%. Given Jasper Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Jasper Therapeutics is more favorable than Psyence Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jasper Therapeutics	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33
Psyence Biomedical	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Psyence Biomedical had 1 more articles in the media than Jasper Therapeutics. MarketBeat recorded 1 mentions for Psyence Biomedical and 0 mentions for Jasper Therapeutics. Psyence Biomedical's average media sentiment score of 1.38 beat Jasper Therapeutics' score of 0.00 indicating that Psyence Biomedical is being referred to more favorably in the news media.

Company	Overall Sentiment
Jasper Therapeutics	Neutral
Psyence Biomedical	Positive

Summary

Psyence Biomedical beats Jasper Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Psyence Biomedical compare to Biofrontera?

Biofrontera (NASDAQ:BFRI) and Psyence Biomedical (NASDAQ:PBM) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and media sentiment.

Psyence Biomedical has a net margin of 0.00% compared to Biofrontera's net margin of -25.66%. Psyence Biomedical's return on equity of 0.00% beat Biofrontera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biofrontera	-25.66%	-515.34%	-53.91%
Psyence Biomedical	N/A	N/A	N/A

10.1% of Biofrontera shares are owned by institutional investors. Comparatively, 77.4% of Psyence Biomedical shares are owned by institutional investors. 8.1% of Biofrontera shares are owned by insiders. Comparatively, 3.6% of Psyence Biomedical shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biofrontera	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Psyence Biomedical	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Biofrontera and Biofrontera both had 1 articles in the media. Psyence Biomedical's average media sentiment score of 1.38 beat Biofrontera's score of 0.00 indicating that Psyence Biomedical is being referred to more favorably in the news media.

Company	Overall Sentiment
Biofrontera	Neutral
Psyence Biomedical	Positive

Psyence Biomedical has lower revenue, but higher earnings than Biofrontera. Biofrontera is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biofrontera	$41.71M	0.31	-$10.54M	-$0.97	N/A
Psyence Biomedical	N/A	N/A	$1.01M	$25.34	0.11

Biofrontera has a beta of 0.83, meaning that its stock price is 17% less volatile than the broader market. Comparatively, Psyence Biomedical has a beta of 1.64, meaning that its stock price is 64% more volatile than the broader market.

Summary

Psyence Biomedical beats Biofrontera on 9 of the 13 factors compared between the two stocks.

How does Psyence Biomedical compare to Pasithea Therapeutics?

Pasithea Therapeutics (NASDAQ:KTTA) and Psyence Biomedical (NASDAQ:PBM) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations, profitability and earnings.

Pasithea Therapeutics has a beta of 0.25, meaning that its stock price is 75% less volatile than the broader market. Comparatively, Psyence Biomedical has a beta of 1.64, meaning that its stock price is 64% more volatile than the broader market.

23.9% of Pasithea Therapeutics shares are held by institutional investors. Comparatively, 77.4% of Psyence Biomedical shares are held by institutional investors. 2.0% of Pasithea Therapeutics shares are held by company insiders. Comparatively, 3.6% of Psyence Biomedical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Psyence Biomedical had 1 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 1 mentions for Psyence Biomedical and 0 mentions for Pasithea Therapeutics. Psyence Biomedical's average media sentiment score of 1.38 beat Pasithea Therapeutics' score of 0.00 indicating that Psyence Biomedical is being referred to more favorably in the news media.

Company	Overall Sentiment
Pasithea Therapeutics	Neutral
Psyence Biomedical	Positive

Pasithea Therapeutics currently has a consensus target price of $3.00, suggesting a potential upside of 439.67%. Given Pasithea Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Pasithea Therapeutics is more favorable than Psyence Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pasithea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Psyence Biomedical	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Psyence Biomedical's return on equity of 0.00% beat Pasithea Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pasithea Therapeutics	N/A	-57.44%	-53.61%
Psyence Biomedical	N/A	N/A	N/A

Pasithea Therapeutics is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pasithea Therapeutics	N/A	N/A	-$20.43M	-$2.08	N/A
Psyence Biomedical	N/A	N/A	$1.01M	$25.34	0.11

Summary

Psyence Biomedical beats Pasithea Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Psyence Biomedical compare to Akari Therapeutics?

Akari Therapeutics (NASDAQ:AKTX) and Psyence Biomedical (NASDAQ:PBM) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akari Therapeutics	N/A	N/A	-$17.30M	N/A	N/A
Psyence Biomedical	N/A	N/A	$1.01M	$25.34	0.11

In the previous week, Akari Therapeutics and Akari Therapeutics both had 1 articles in the media. Psyence Biomedical's average media sentiment score of 1.38 beat Akari Therapeutics' score of 0.67 indicating that Psyence Biomedical is being referred to more favorably in the news media.

Company	Overall Sentiment
Akari Therapeutics	Positive
Psyence Biomedical	Positive

5.1% of Akari Therapeutics shares are owned by institutional investors. Comparatively, 77.4% of Psyence Biomedical shares are owned by institutional investors. 32.2% of Akari Therapeutics shares are owned by insiders. Comparatively, 3.6% of Psyence Biomedical shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Akari Therapeutics currently has a consensus price target of $89.00, indicating a potential upside of 727.14%. Given Akari Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Akari Therapeutics is more favorable than Psyence Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akari Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Psyence Biomedical	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Akari Therapeutics has a beta of 1.33, meaning that its share price is 33% more volatile than the broader market. Comparatively, Psyence Biomedical has a beta of 1.64, meaning that its share price is 64% more volatile than the broader market.

Psyence Biomedical's return on equity of 0.00% beat Akari Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Akari Therapeutics	N/A	-123.29%	-63.01%
Psyence Biomedical	N/A	N/A	N/A

Summary

Psyence Biomedical beats Akari Therapeutics on 6 of the 10 factors compared between the two stocks.

How does Psyence Biomedical compare to Phio Pharmaceuticals?

Phio Pharmaceuticals (NASDAQ:PHIO) and Psyence Biomedical (NASDAQ:PBM) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, analyst recommendations, profitability, institutional ownership and valuation.

In the previous week, Phio Pharmaceuticals and Phio Pharmaceuticals both had 1 articles in the media. Psyence Biomedical's average media sentiment score of 1.38 beat Phio Pharmaceuticals' score of 0.00 indicating that Psyence Biomedical is being referred to more favorably in the news media.

Company	Overall Sentiment
Phio Pharmaceuticals	Neutral
Psyence Biomedical	Positive

Phio Pharmaceuticals is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phio Pharmaceuticals	N/A	N/A	-$8.70M	-$1.38	N/A
Psyence Biomedical	N/A	N/A	$1.01M	$25.34	0.11

57.3% of Phio Pharmaceuticals shares are held by institutional investors. Comparatively, 77.4% of Psyence Biomedical shares are held by institutional investors. 0.9% of Phio Pharmaceuticals shares are held by company insiders. Comparatively, 3.6% of Psyence Biomedical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Phio Pharmaceuticals presently has a consensus price target of $14.00, indicating a potential upside of 1,272.55%. Given Phio Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Phio Pharmaceuticals is more favorable than Psyence Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phio Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Psyence Biomedical	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Psyence Biomedical's return on equity of 0.00% beat Phio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phio Pharmaceuticals	N/A	-77.34%	-70.87%
Psyence Biomedical	N/A	N/A	N/A

Phio Pharmaceuticals has a beta of 0.82, suggesting that its stock price is 18% less volatile than the broader market. Comparatively, Psyence Biomedical has a beta of 1.64, suggesting that its stock price is 64% more volatile than the broader market.

Summary

Psyence Biomedical beats Phio Pharmaceuticals on 9 of the 12 factors compared between the two stocks.

Get Psyence Biomedical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PBM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PBM vs. The Competition

Export

Metric	Psyence Biomedical	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.97M	$3.49B	$6.74B	$12.32B
Dividend Yield	N/A	2.28%	2.68%	5.88%
P/E Ratio	0.11	20.50	25.39	23.96
Price / Sales	N/A	328.65	530.17	107.90
Price / Cash	0.26	130.96	45.29	53.76
Price / Book	0.04	8.26	10.76	6.41
Net Income	$1.01M	$23.91M	$3.56B	$337.14M
7 Day Performance	-12.70%	2.12%	0.98%	-1.06%
1 Month Performance	-32.93%	2.40%	0.78%	0.49%
1 Year Performance	-91.08%	57.09%	30.24%	28.43%

Psyence Biomedical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PBM Psyence Biomedical	1.877 of 5 stars	$2.75 -5.5%	N/A	-91.3%	$2.97M	N/A	0.11	N/A	Positive News Earnings Report
JSPR Jasper Therapeutics	2.6074 of 5 stars	$0.45 -3.9%	$13.14 +2,801.3%	-91.2%	$12.68M	N/A	N/A	20	Gap Up
BFRI Biofrontera	0.9253 of 5 stars	$0.99 +0.6%	N/A	+56.0%	$12.64M	$43.20M	N/A	70
KTTA Pasithea Therapeutics	2.9455 of 5 stars	$0.50 +0.1%	$3.00 +496.4%	-24.0%	$12.55M	N/A	N/A	3
AKTX Akari Therapeutics	2.3947 of 5 stars	$10.94 -8.8%	$89.00 +713.5%	-76.8%	$12.47M	N/A	N/A	9

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PBM) was last updated on 6/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Psyence Biomedical (PBM) Competitors

PBM vs. JSPR, BFRI, KTTA, AKTX, and PHIO

How does Psyence Biomedical compare to Jasper Therapeutics?

Summary

How does Psyence Biomedical compare to Biofrontera?

Summary

How does Psyence Biomedical compare to Pasithea Therapeutics?

Summary

How does Psyence Biomedical compare to Akari Therapeutics?

Summary

How does Psyence Biomedical compare to Phio Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PBM vs. The Competition

Psyence Biomedical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Psyence Biomedical (PBM) Competitors

PBM vs. JSPR, BFRI, KTTA, AKTX, and PHIO

How does Psyence Biomedical compare to Jasper Therapeutics?

Is JSPR or PBM more profitable?

Which has more volatility and risk, JSPR or PBM?

Which has better earnings & valuation, JSPR or PBM?

Do institutionals & insiders have more ownership in JSPR or PBM?

Do analysts recommend JSPR or PBM?

Does the media refer more to JSPR or PBM?

Summary

How does Psyence Biomedical compare to Biofrontera?

Is BFRI or PBM more profitable?

Do institutionals and insiders hold more shares of BFRI or PBM?

Do analysts prefer BFRI or PBM?

Does the media favor BFRI or PBM?

Which has preferable valuation & earnings, BFRI or PBM?

Which has more risk & volatility, BFRI or PBM?

Summary

How does Psyence Biomedical compare to Pasithea Therapeutics?

Which has more risk & volatility, KTTA or PBM?

Do insiders & institutionals believe in KTTA or PBM?

Does the media favor KTTA or PBM?

Do analysts recommend KTTA or PBM?

Is KTTA or PBM more profitable?

Which has better earnings and valuation, KTTA or PBM?

Summary

How does Psyence Biomedical compare to Akari Therapeutics?

Which has stronger valuation and earnings, AKTX or PBM?

Does the media refer more to AKTX or PBM?

Do insiders & institutionals hold more shares of AKTX or PBM?

Do analysts prefer AKTX or PBM?

Which has more volatility and risk, AKTX or PBM?

Is AKTX or PBM more profitable?

Summary

How does Psyence Biomedical compare to Phio Pharmaceuticals?

Does the media favor PHIO or PBM?

Which has stronger earnings & valuation, PHIO or PBM?

Do institutionals & insiders have more ownership in PHIO or PBM?

Do analysts prefer PHIO or PBM?

Is PHIO or PBM more profitable?

Which has more volatility and risk, PHIO or PBM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PBM vs. The Competition

Psyence Biomedical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools